Lisocabtagene Maraleucel and the Transforming Treatment Landscape for Large B-Cell Lymphoma: Manali Kamdar, MD

For patients with relapsed/refractory large B-cell lymphoma (LBCL), treatment options are limited, and outcomes remain poor with the current standard of care. In the phase 3 TRANSFORM trial, Dr. Manali Kamdar, Clinical Director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, and colleagues investigated the efficacy of lisocabtagene maraleucel (liso-cel), an anti-CD19–directed chimeric antigen receptor (CAR) T-cell therapy, in this setting. Dr. Kamdar recently pres...

Continue reading

Lisocabtagene Maraleucel Approved for Relapsed/Refractory Large B-Cell Lymphoma

The FDA has granted approval to lisocabtagene maraleucel (liso-cel) (Breyanzi®, Bristol Myers Squibb™) for treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after one prior therapy who have become R/R within 12 months of first-line therapy, or who have become R/R after the first line of therapy and are not eligible for hematopoietic stem cell transplant (HSCT). The approval was based on the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 PILOT study (NCT0...

Continue reading

Lisocabtagene Maraleucel Approved for Relapsed/Refractory Large B-Cell Lymphomas

The FDA has approved lisocabtagene maraleucel (Breyanzi®, Juno Therapeutics) for patients with relapsed/refractory large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DCBLC transformed from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, and grade 3B follicular lymphoma, who have progressive disease following at least two prior lines of systemic therapy. Lisocabtagene maraleucel is not indicated for patie...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.